For the quarter ending 2026-03-31, BIOA had $52,889K increase in cash & cash equivalents over the period. -$24,072K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -22,253 | -25,943 | -20,171 | -34,491 |
| Stock-based compensation expense | 4,256 | 2,722 | 2,791 | 6,178 |
| Depreciation expense | 63 | 69 | 49 | 95 |
| Loss on extinguishment of debt | - | 0 | 0 | 0 |
| Non-cash interest expense | 16 | 7 | 16 | 140 |
| Non-cash lease expense | 65 | 10 | 2 | 113 |
| (gain) loss from changes in fair value on warrants | 107 | 220 | 42 | -48 |
| Loss on disposal of property and equipment | - | -23 | - | - |
| Accretion of net investment discounts | 306 | 1,623 | - | - |
| Accounts receivable | -60 | 254 | -88 | 603 |
| Prepaid expenses and other current assets | 2,975 | 232 | 436 | 1,045 |
| Other assets | -1 | -11 | -10 | -3 |
| Accounts payable | 326 | -2,307 | 3,645 | -550 |
| Accrued expenses and other current liabilities | -3,843 | 1,354 | -542 | -4,224 |
| Deferred grant income | - | 0 | - | - |
| Deferred revenue | 437 | -2,308 | -1,538 | -2,900 |
| Deferred grant income | - | - | 0 | - |
| Net cash used in operating activities | -24,046 | -28,251 | -16,044 | -37,332 |
| Purchase of property and equipment | 26 | 112 | 22 | 585 |
| Purchases of marketable securities | 80,214 | 40,316 | 12,887 | 101,544 |
| Maturities of marketable securities | 33,487 | 26,000 | 25,750 | 8,500 |
| Net cash used in investing activities | -46,753 | -14,428 | 12,841 | -93,629 |
| Proceeds from series d issuance | - | 0 | 0 | 0 |
| Proceeds from underwritten offering of common stock, net of underwriting discounts and commissions | 124,315 | - | - | - |
| Underwritten offering issuance costs paid | 716 | 0 | 0 | 0 |
| Proceeds from initial public offering, net of underwriting discounts and commissions | - | 0 | 0 | - |
| Issuance costs paid on initial public offering and private placement | - | 0 | 0 | - |
| Proceeds from issuance of common shares through private placement, net of placement agent fees | - | 0 | 0 | - |
| Proceeds from issuance of common stock through at-the-market facility, net of commissions | - | 17,155 | - | - |
| Issuance costs paid on at-the market offering | - | 64 | - | - |
| Deferred offering costs paid | 91 | 292 | 44 | 0 |
| Term loan principal payments | 1,500 | 1,500 | 1,500 | 3,000 |
| Proceeds from issuance of common shares upon stock option exercises | 1,707 | 714 | 0 | 0 |
| Net cash provided by (used in) financing activities | 123,715 | 16,013 | -1,544 | -3,000 |
| Effect of changes in exchange rate on cash and cash equivalents | -27 | -19 | -10 | -58 |
| Net increase (decrease) in cash and cash equivalents | 52,889 | -26,685 | -4,757 | -134,019 |
| Cash and cash equivalents at end of period | 188,888 | 354,349 | 354,349 | - |
| Cash and cash equivalents at end of period | 241,777 | 188,888 | 215,573 | - |
BioAge Labs, Inc. (BIOA)
BioAge Labs, Inc. (BIOA)